ES2655505T3 - Producto y procedimiento para el tratamiento de la diarrea - Google Patents
Producto y procedimiento para el tratamiento de la diarrea Download PDFInfo
- Publication number
- ES2655505T3 ES2655505T3 ES14722445.5T ES14722445T ES2655505T3 ES 2655505 T3 ES2655505 T3 ES 2655505T3 ES 14722445 T ES14722445 T ES 14722445T ES 2655505 T3 ES2655505 T3 ES 2655505T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- patients
- diarrhea
- group
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 6
- 238000000034 method Methods 0.000 title description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 abstract description 2
- 229960001803 cetirizine Drugs 0.000 abstract description 2
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 229960001508 levocetirizine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 208000019902 chronic diarrheal disease Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Antagonista del receptor H1 y antagonista del receptor H2 para utilizar en el tratamiento de la diarrea en un paciente, en el que el paciente presenta diarrea inducida por quimioterapia, y el antagonista del receptor H1 comprende cetirizina, levocetirizina o mezclas de las mismas.
Description
- deposiciones
- 6
- 0%
- 0
- 10-25%
- 1
- 28-45%
- 1
- 50-65%
- 0
- 66-85%
- 0
- > 86%
Ejemplo 8: Estudio del Tratamiento de la diarrea crónica (no es parte de la invención)
La edad de la población del estudio fue de 21 a 70, con pacientes con diagnóstico de diarrea crónica, que dieron su
5 consentimiento para el tratamiento. Se excluyeron los pacientes si había una sensibilidad o alergia a los antagonistas del receptor H1 o antagonistas del receptor H2, insuficiencia renal o historial de insuficiencia renal, un diagnóstico de enfermedad inflamatoria del intestino (enfermedad de Crohn o colitis ulcerosa), una infección activa conocida del colon (tal como Clostridium difficile, giardia o Salmonella), colitis microscópica demostrada por biopsia (colitis colagenosa o linfocítica), o una incapacidad para suspender otros agentes anti-diarreicos durante el estudio. Los pacientes también
10 fueron excluidos si eran mujeres embarazadas o en periodo de lactancia, o si el paciente estaba tomando atazanavir, itraconazol o ketoconazol. El estudio fue iniciado después de la aprobación del IRB.
El estudio fue un ensayo comparativo, doble ciego, de distribución aleatoria, durante 4 semanas, con cruzamiento. Después de obtener el consentimiento informado, los pacientes fueron asignados aleatoriamente a uno de los dos grupos 15 (activo o placebo), sin saber los pacientes ni los médicos a qué grupo fue asignado cada paciente. A cada paciente se le proporcionó el procedimiento de tratamiento que le fue asignado al azar y se le dio un diario para documentar los síntomas. Después de 7 días de tratamiento, los individuos participaron en una entrevista telefónica con un miembro del equipo de investigación que desconocía el tratamiento. Se permitió el cruzamiento después de una semana de tratamiento para quienes no tuvieron respuesta. Al final del estudio de 28 días, los pacientes completaron un cuestionario detallado. La
20 calidad de las heces se evaluó utilizando la Escala de heces de Bristol de 7 puntos.
El grupo "activo" recibió famotidina (24 mg) y cetirizina (9 mg), una vez por día, con ambos fármacos combinados en forma de una sola cápsula. El grupo "placebo" recibió una cápsula una vez al día, que no contenía principios activos.
25 Los resultados del estudio se muestran en la Tabla 6. La tabla muestra los resultados de 27 pacientes, 12 en el grupo placebo y 15 en el grupo activo. El valor promedio del porcentaje de cambio de heces por día (HPD) fue 25,08 para el grupo placebo, mientras que el valor promedio para un cambio de porcentaje en HPD fue 46,00 para el grupo activo. Sólo 3 de los pacientes del grupo activo aceptaron el cruzamiento, mientras que 9 de los pacientes del grupo placebo acordaron el cruzamiento. Los datos demuestran una significación clínica entre el grupo placebo y el grupo activo, y demuestran una
30 mejora significativa en la calidad de vida de los pacientes en el grupo activo.
Tabla 6: Resultados del Estudio del tratamiento de Diarrea crónica
- Grupo
- Número de pacientes Promedio Δ% HPD
- Placebo
- 12 25.08
- Activo
- 15 46.00
Schiller LR, "Secretory Diarrhea" Current Gastroenterology Reports (1999) 1: 389-397.
Schiller, LR, Hogan RB, Morawski, SG, Santa Ana, CA, Bern MJ, Nogaard, RP, Bo-Linn, GW, Fordtran JS, "Studies of the 40 Prevalence and Significance of Radiolabeled Rice Acid Malabsorption in a Group of Patients with Idiopathic Chronic Diarrhea" Gastroenterology (1997) 92:151-160.
Fordtran JS, Santa Ana CA, Morawski SG, et al. "Pathophysiology of chronic diarrhea: insights derived from intestinal perfusion studies in 31 patients" Gastroenterol Clin North Am (1986) 15:477-490.
45
9
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782608P | 2013-03-14 | 2013-03-14 | |
| US201361782608P | 2013-03-14 | ||
| PCT/US2014/027323 WO2014152420A2 (en) | 2013-03-14 | 2014-03-14 | Product and method for treating diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655505T3 true ES2655505T3 (es) | 2018-02-20 |
Family
ID=50680150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14722445.5T Active ES2655505T3 (es) | 2013-03-14 | 2014-03-14 | Producto y procedimiento para el tratamiento de la diarrea |
| ES17189072T Active ES2743604T3 (es) | 2013-03-14 | 2014-03-14 | Producto y procedimiento para el tratamiento de la diarrea |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17189072T Active ES2743604T3 (es) | 2013-03-14 | 2014-03-14 | Producto y procedimiento para el tratamiento de la diarrea |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9717726B2 (es) |
| EP (3) | EP2968205B1 (es) |
| JP (4) | JP6313417B2 (es) |
| KR (4) | KR20180088514A (es) |
| CN (2) | CN108939076A (es) |
| AU (3) | AU2014239878B2 (es) |
| BR (2) | BR122017004716A2 (es) |
| CA (1) | CA2906005C (es) |
| DK (1) | DK2968205T3 (es) |
| ES (2) | ES2655505T3 (es) |
| HK (1) | HK1247557B (es) |
| HU (1) | HUE035201T2 (es) |
| IL (3) | IL273377B2 (es) |
| MX (2) | MX350814B (es) |
| MY (1) | MY175326A (es) |
| PL (1) | PL2968205T3 (es) |
| PT (1) | PT2968205T (es) |
| RU (1) | RU2015143475A (es) |
| WO (1) | WO2014152420A2 (es) |
| ZA (1) | ZA201708539B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717726B2 (en) * | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| WO2015073573A1 (en) * | 2013-11-14 | 2015-05-21 | Jacobs Michael M | Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome |
| EP3558296B1 (en) | 2016-12-23 | 2023-06-28 | Maregade RX, LLC | Low dose product and method for treating diarrhea |
| IT201900012645A1 (it) * | 2019-07-23 | 2021-01-23 | Eros Zanotti | Una composizione farmaceutica per l'uso nel trattamento delle chinetosi |
| CN117293008A (zh) * | 2019-08-05 | 2023-12-26 | 株式会社日立高新技术 | 等离子处理装置 |
| US20220408780A1 (en) * | 2020-02-11 | 2022-12-29 | The E. Wolfson Medical Center | A method effective for treating ulcerative colitis |
| KR102936883B1 (ko) | 2021-08-23 | 2026-03-11 | 주식회사 히타치하이테크 | 플라스마 처리 장치 및 플라스마 처리 방법 |
| EP4408414A4 (en) * | 2021-09-22 | 2025-10-22 | Hista Rx Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF INTERSTITIAL CYSTITIS |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| US5096894A (en) * | 1990-04-03 | 1992-03-17 | Bristol-Myers Squibb Company | Rice dextrin oral rehydration solution |
| AU7255094A (en) | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-antihistamine combinations |
| US6264984B1 (en) * | 1999-12-06 | 2001-07-24 | Bristol-Myers Squibb Company | Effervescent histamine H2 antagonist composition |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| BR0116178A (pt) | 2000-11-30 | 2003-10-14 | Bio Balance Corp | Cepa bacterial, composição probiótica compreendendo uma cepa bacterial, formulação compreendendo pelo menos uma fração volátil de um extrato de planta, aditivo alimentar, processo de preparação de uma fração volátil de uma planta, processo de preparação de uma formulação terapêutica, processo de crescimento de uma cepa bacterial, processo de manufatura de uma composição probiótica, processo de preparo de uma composição probiótica, processo de preparo de uma composição incluindo microorganismos viáveis, dispensador de microorganismo, método de bio controle de um organismo, método para eliminar uma poluição de óleo, método de recuperação de fumaças orgnicas, produto alimentar e método de preparo inicial para um processo de fermantação |
| AU2002356715B2 (en) * | 2001-11-23 | 2008-05-15 | Janssen Pharmaceutica N.V. | The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| SE528789C2 (sv) | 2004-09-10 | 2007-02-13 | Sandvik Intellectual Property | PVD-belagt skär av hårdmetall samt sätt att tillverka detta |
| US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
| US20090312358A1 (en) | 2006-03-22 | 2009-12-17 | Trustees Of Boston University | Method for management of diarrhea |
| US8207188B2 (en) | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
| US20070254050A1 (en) * | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
| US20090042972A1 (en) * | 2006-05-19 | 2009-02-12 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
| EP2559434A3 (en) | 2007-02-12 | 2013-05-29 | Mike Nicolaou | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
| CA2721133C (en) * | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| ES2686129T3 (es) | 2012-11-13 | 2018-10-16 | Codiak Biosciences, Inc. | Administración de agentes terapéuticos |
| US9717726B2 (en) * | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| EP3558296B1 (en) | 2016-12-23 | 2023-06-28 | Maregade RX, LLC | Low dose product and method for treating diarrhea |
-
2014
- 2014-03-13 US US14/209,937 patent/US9717726B2/en active Active
- 2014-03-14 EP EP14722445.5A patent/EP2968205B1/en active Active
- 2014-03-14 KR KR1020187021688A patent/KR20180088514A/ko not_active Ceased
- 2014-03-14 ES ES14722445.5T patent/ES2655505T3/es active Active
- 2014-03-14 KR KR1020217004881A patent/KR102449977B1/ko active Active
- 2014-03-14 EP EP19169633.5A patent/EP3581205A3/en active Pending
- 2014-03-14 KR KR1020207023569A patent/KR20200100211A/ko not_active Ceased
- 2014-03-14 RU RU2015143475A patent/RU2015143475A/ru not_active Application Discontinuation
- 2014-03-14 MX MX2015011885A patent/MX350814B/es active IP Right Grant
- 2014-03-14 MY MYPI2015703092A patent/MY175326A/en unknown
- 2014-03-14 WO PCT/US2014/027323 patent/WO2014152420A2/en not_active Ceased
- 2014-03-14 BR BR122017004716-7A patent/BR122017004716A2/pt not_active Application Discontinuation
- 2014-03-14 EP EP17189072.6A patent/EP3269364B1/en active Active
- 2014-03-14 JP JP2016502404A patent/JP6313417B2/ja active Active
- 2014-03-14 BR BR112015022513A patent/BR112015022513A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2017011532A patent/MX366329B/es unknown
- 2014-03-14 CN CN201810755897.7A patent/CN108939076A/zh active Pending
- 2014-03-14 KR KR1020157029028A patent/KR101884506B1/ko active Active
- 2014-03-14 ES ES17189072T patent/ES2743604T3/es active Active
- 2014-03-14 PL PL14722445T patent/PL2968205T3/pl unknown
- 2014-03-14 HU HUE14722445A patent/HUE035201T2/hu unknown
- 2014-03-14 PT PT147224455T patent/PT2968205T/pt unknown
- 2014-03-14 CA CA2906005A patent/CA2906005C/en active Active
- 2014-03-14 CN CN201480022471.0A patent/CN105324112B/zh active Active
- 2014-03-14 AU AU2014239878A patent/AU2014239878B2/en active Active
- 2014-03-14 IL IL273377A patent/IL273377B2/en unknown
- 2014-03-14 DK DK14722445.5T patent/DK2968205T3/da active
-
2015
- 2015-09-09 IL IL241372A patent/IL241372B/en active IP Right Grant
-
2016
- 2016-09-06 US US15/257,674 patent/US10034875B2/en active Active
-
2017
- 2017-10-24 AU AU2017251701A patent/AU2017251701B2/en active Active
- 2017-12-13 IL IL256300A patent/IL256300B/en active IP Right Grant
- 2017-12-15 ZA ZA2017/08539A patent/ZA201708539B/en unknown
-
2018
- 2018-03-22 JP JP2018054088A patent/JP6473254B2/ja active Active
- 2018-05-28 HK HK18106976.5A patent/HK1247557B/en unknown
- 2018-07-06 US US16/029,384 patent/US11058681B2/en active Active
-
2019
- 2019-01-24 JP JP2019009896A patent/JP6790140B2/ja active Active
- 2019-02-28 AU AU2019201412A patent/AU2019201412A1/en not_active Abandoned
-
2020
- 2020-11-04 JP JP2020184294A patent/JP2021046400A/ja active Pending
-
2021
- 2021-05-28 US US17/333,525 patent/US20220047583A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2655505T3 (es) | Producto y procedimiento para el tratamiento de la diarrea | |
| Dimopoulos et al. | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study | |
| Villanueva et al. | β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial | |
| Lataillade et al. | Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study | |
| Smith et al. | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial | |
| Brose et al. | Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial | |
| Perl et al. | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study | |
| Muthuri et al. | Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data | |
| Koopman et al. | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial | |
| Yahata et al. | Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin | |
| Teerlink et al. | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial | |
| CR20230330A (es) | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso | |
| Jamal et al. | A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain | |
| Langer et al. | Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer | |
| US8697662B2 (en) | Methods for treating Kaposi sarcoma | |
| Oelke et al. | Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged≥ 75 years: integrated analyses of pooled data from multinational, randomized, placebo‐controlled clinical studies | |
| Jain et al. | Anaphylaxis following intravenous paracetamol: the problem is the solution | |
| Mallet et al. | Major depressive disorder (MDD) and schizophrenia–Addressing unmet needs with partial agonists at the D2 receptor: A review | |
| Capetti et al. | Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection | |
| Mateos et al. | Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials | |
| Olin et al. | Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26‐week, open‐label, prospective trial (Study ENA713B US32) | |
| Arends et al. | Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis | |
| Raedler | Akynzeo (Netupitant and Palonosetron), a dual-acting oral agent, approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting | |
| Mave et al. | Tuberculosis disease among people with HIV: therapeutic advances | |
| Scagliotti et al. | A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy |